Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Haemonetics (HAE) PT Lowered to $86 at Needham & Company
May 13, 2021 1:03 PM EDTNeedham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $86.00 (from $108.00) while maintaining a Buy rating.
The analyst commented, "HAE's F4Q21 revenue beat and EPS missed consensus. HAE's organic growth slowed to (13.7%) in F4Q21 vs. (5.7%)... More
Jefferies Sees Haemonetics (HAE) as Oversold Ahead of Earnings, PT Lowered $105
May 12, 2021 8:10 AM EDTJefferies analyst Anthony Petrone lowered the price target on Haemonetics (NYSE: HAE) to $105.00 (from $185.00) ahead of the F4Q earnings call scheduled for 5/13 BMO. Focus points for the call are expected to include: 1) detail/commentary on CSL's plasma supply chain shift toward Terumo; 2) future contracting implications, 3)... More
